An indigenous, low-cost HPV test known as Truenat HR-HPV-Plus has been validated to meet international standards for cervical cancer screening, potentially expanding access for millions of women in India. According to a study published in the International Journal of Cancer in June, the assay is the first of its kind to meet the International Agency for Research on Cancer (IARC) criteria for high-risk HPV detection, offering a scalable alternative to expensive, lab-heavy testing methods.
Why is this new validation important for cervical cancer screening?
The validation of Truenat HR-HPV-Plus provides a reliable, cost-effective tool for a country where cervical cancer claims roughly 80,000 lives annually. Dr. Neerja Bhatla, Professor Emeritus at the National Cancer Institute, AIIMS, Jhajjar, noted that while the cause and prevention of cervical cancer are well-understood, screening often fails to reach women in the right setting. By meeting international standards for sensitivity and specificity, this indigenous test addresses the primary barriers to adoption: high costs and complex infrastructure requirements.
Approximately eight out of 10 women will contract the human papillomavirus (HPV) at some point in their lives, putting over 480 million women in India at risk of infection-related complications.
How does the test perform against international benchmarks?
The study reported that the test achieved 80.4% sensitivity and 91.5% specificity for detecting cervical intraepithelial neoplasia grade 2 or worse, which is a critical precursor to cancer. These findings were based on data from the ESTAMPA study, a multi-centric screening program that monitored 44,135 women in Latin America between 2012 and 2022. According to the research team, this high level of specificity is vital because it reduces the number of unnecessary clinical referrals and follow-up procedures, making it a more efficient option for public health systems.
What are the next steps for women’s health in India?
Health experts emphasize that early detection is the most effective way to lower mortality rates. The World Health Organization (WHO) currently recommends that women undergo screening twice in their lifetime, specifically at age 35 and 45. Dr. Bhatla emphasizes that consistent screening for women over 30 is necessary to manage risk effectively. With the introduction of this validated, indigenous tool, officials hope to lower the current 127,000 annual new case rate by shifting away from laboratory-intensive diagnostics toward more accessible, decentralized testing.
Comparison: Traditional vs. New Screening Barriers
| Feature | Traditional HPV Tests | Truenat HR-HPV-Plus |
|---|---|---|
| Cost | Often prohibitive | Low-cost/Scalable |
| Infrastructure | High-tech labs required | Field-deployable |
Frequently Asked Questions
Who should get screened for cervical cancer?
The WHO recommends that women undergo screening at age 35 and again at age 45 using validated HPV tests.
Is cervical cancer preventable?
Yes. According to public health data, cervical cancer is one of the most preventable and treatable forms of cancer through vaccination, early screening, and timely treatment of precancerous cells.
Why have HPV test adoption rates been low in India?
Researchers cite high costs, the need for specialized laboratory infrastructure, long turnaround times, and difficulties in ensuring patient follow-ups as the primary reasons for low adoption.
Have questions about your own screening schedule? Consult your primary care physician or local health clinic for guidelines tailored to your medical history. Subscribe to our newsletter for the latest updates on medical technology and public health initiatives.
